158 related articles for article (PubMed ID: 38026790)
1. Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement.
Li J; Zong S; Wan Y; Ruan M; Zhang L; Yang W; Chen X; Zou Y; Chen Y; Guo Y; Wu P; Zhang Y; Zhu X
Hemasphere; 2023 Dec; 7(12):e979. PubMed ID: 38026790
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
4. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
6. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
[TBL] [Abstract][Full Text] [Related]
7. Updates in
Górecki M; Kozioł I; Kopystecka A; Budzyńska J; Zawitkowska J; Lejman M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979800
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
[TBL] [Abstract][Full Text] [Related]
9. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
[TBL] [Abstract][Full Text] [Related]
10. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract][Full Text] [Related]
11. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Menghrajani K; Gomez-Arteaga A; Madero-Marroquin R; Zhang MJ; Bo-Subait K; Sanchez J; Wang HL; Aljurf M; Assal A; Bacher VU; Badawy SM; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Castillo P; Cerny J; Chhabra S; Ciurea SO; DeFilipp Z; Farhadfar N; Gadalla S; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt G; Kanakry CG; Kansagra A; Khimani F; Krem M; Lazarus H; Liu H; Martino R; Michelis FV; Nathan S; Nishihori T; Olsson R; Reshef R; Rizzieri D; Rowe JM; Savani BN; Seo S; Sharma A; Solh M; Ustun C; Verdonck LF; Hourigan C; Sandmaier B; Litzow M; Kebriaei P; Weisdorf D; Zhang Y; Tallman MS; Saber W
Blood Adv; 2022 Jan; 6(3):828-847. PubMed ID: 34551064
[TBL] [Abstract][Full Text] [Related]
12. Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia.
Hoffmeister LM; Orhan E; Walter C; Niktoreh N; Hanenberg H; von Neuhoff N; Reinhardt D; Schneider M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638301
[No Abstract] [Full Text] [Related]
13. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
[TBL] [Abstract][Full Text] [Related]
14. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
[TBL] [Abstract][Full Text] [Related]
15. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
[TBL] [Abstract][Full Text] [Related]
16. Pediatric acute myeloid leukemia patients with
Yang W; Qin M; Jia C; Yang J; Chen W; Luo Y; Jing Y; Wang B
Hematology; 2022 Dec; 27(1):583-589. PubMed ID: 35617149
[TBL] [Abstract][Full Text] [Related]
17. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
Tregnago C; Benetton M; Da Ros A; Borella G; Longo G; Polato K; Francescato S; Biffi A; Pigazzi M
Front Pharmacol; 2021; 12():820191. PubMed ID: 35153769
[TBL] [Abstract][Full Text] [Related]
18. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Villenet C; Petit A; Rousseau A; Ng SWK; Paquet A; Gonzales F; Barthélémy A; Leprêtre F; Pottier N; Nelken B; Michel G; Baruchel A; Bertrand Y; Leverger G; Lapillonne H; Figeac M; Dick JE; Wang JCY; Preudhomme C; Cheok M
Leukemia; 2019 Feb; 33(2):348-357. PubMed ID: 30089916
[TBL] [Abstract][Full Text] [Related]
19. Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway.
Cai X; Wang J; Lu J; Jia Z; Chen M; Liu J; Lu X; Chao H
Acta Haematol; 2022; 145(2):144-151. PubMed ID: 34551411
[TBL] [Abstract][Full Text] [Related]
20. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
Issa GC; Zarka J; Sasaki K; Qiao W; Pak D; Ning J; Short NJ; Haddad F; Tang Z; Patel KP; Cuglievan B; Daver N; DiNardo CD; Jabbour E; Kadia T; Borthakur G; Garcia-Manero G; Konopleva M; Andreeff M; Kantarjian HM; Ravandi F
Blood Cancer J; 2021 Sep; 11(9):162. PubMed ID: 34588432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
